A Phase 2 interventional study of Taurolidine citrate 4% and heparin 500 in Catheter Related Blood Stream Infection, Hemodialysis and Vascular Access, sponsored by Oman Ministry of Health. Completed at 1 site in Oman. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.
Sponsored by Oman Ministry of Health · Phase 2, Interventional, and Prevention
Tunneled hemodialysis catheters are susceptible to infection with high incidence of complication to the hemodialysis patients .The study aimed to prevent catheter infection through comparing use of antimicrobial solution (Taurolidine) when used as lock solution installed in the lumen of the catheter at the end of the hemodialysis session with the usually used lock solution heparin. The Study was performed on 100 hemodialysis patients over one year in Sohar hospital ,Oman .
107 studies on the registry are indexed under Catheter-Related Infections; 16 are open to participants now.
This study's enrollment of 100 is below the median of 150 across 76 interventional studies indexed under Catheter-Related Infections.
Browse Catheter-Related Infections studies →Oman Ministry of Health is the lead sponsor of 18 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
- All clinically stable adult end stage renal disease patients commence regular hemodialysis through tunneled hemodialysis catheter at Sohar hospital hemodialysis unit.
Exclusion criteria:
Measure incidence of catheter related blood stream infection while patients use Heparin as catheter lock
Measure incidence of catheter related blood stream infection while patients use Taurolidine based lock solution as catheter lock
Drug: Taurolidine citrate 4% and heparin 500
Taurolidine ,citrate 4% and heparin 500 units per ml used as lock solution in tunneled hemodialysis catheter
Comparison between both groups in terms of incidence of Catheter related blood stream infection
The investigators have studied the incidence of catheter related bacterial infection in both groups to determine superior effectiveness of Taurolidine lock solution than Heparin lock only in terms of prevention of infection .
Time frame: one year
Comparison between both groups in terms of treatment cost
The secondary outcome measure was to compare the treatment cost in both groups to determine cost effectiveness
Time frame: one year
Plan to share: Yes — Methodology and results
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oman Ministry of Health